Skip to main content

Advertisement

Table 2 Results base case model per surveillance strategy for low and high risk of LRR

From: Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study

  Hospital-based strategy NBCSP-based strategy
Low risk of LRR High risk of LRR Low risk of LRR High risk of LRR
Total number of TTR (positive TTR, negative TTR) 26,663 24,883 13,534 12,923
13 (0.2%) 26,650 (99.8%) 440 (6.5%) 24,443 (93.5%) 8 (0.1%) 13,526 (99.9%) 387 (5.7%) 12,536 (94,3%)
Total costs (€) surveillance 2,529,150 2,367,616 1,063,530 1,013,224
Total costs (€) of treatment 169,152 5,082,534 208,136 5,926,590
Final costs (€) 2,698,302 7,450,150 1,271,666 6,939,814
Early vs late detection of LRR (%) 10 early, 3 late (0.14, 0.04) 298 early, 142 late (4.39, 2.09) 2 early, 6 late (0.03, 0.09) 113 early, 274 late (1.66, 4.03)
Self-detected LRRs after 5 years (%) 3 (0.04) 17 (0.25) 8 (0.11) 66 (0.97)
False positive test results resulting in extra diagnostic tests (%) 461 (6.55) 423 (6.23) 234 (3.32) 217 (3.19)
  1. TTR = True (positive and/or negative) Test Results
  2. LRR = Locoregional Recurrence